Tradestie Institutional Equity Comparison Engine

AXNX vs ABT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABT Overall Edge

ABT Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abbott Laboratories (ABT) driven by superior Valuation, Growth & Margin, Options & Structure while AXNX counters with relative strength in Momentum & Technical. Fundamentally, AXNX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABT at 17.4x Forward P/E and 15.7% operating margin (+14.5% YoY). In options structure, AXNX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABT sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABT
AXNX N/M vs ABT 17.4x Fwd P/E
Growth & Margin Winner ABT
Op Margin N/A vs 15.7% ยท YoY N/A vs +14.5%
Momentum & Technical Winner AXNX
1Y +16.9% vs -18.4% ยท 52W Pos 50% vs 42%
Options & Structure Winner ABT
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (11th %ile IV)
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
1M Return -26.54%
1Y Return +16.92%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
ABT NYSE
Abbott Laboratories
Pharmaceutical Preparations
$103.00
-0.84% 1D
Market Cap $179.9B
1M Return +0.48%
1Y Return -18.35%
Forward P/E 17.4x
Unified AI Score
42.6 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AXNX +16.92% ABT -18.35% Spread: +16.54 pp (AXNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AXNX TTM Op. Margin: N/A ABT TTM Op. Margin: 15.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs ABT. Trailing 12-month operating profitability (AXNX N/A vs ABT 15.7%) and valuation multiples (AXNX N/M vs ABT 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AXNX (2) vs ABT (8)
Institutional Metric AXNX ABT Criterion Row Winner
Market Capitalization Scale N/A $179.9B Larger Scale ABT
Trailing P/E Ratio Valuation N/M 38.8x Lower Multiple ABT
Forward P/E Ratio Valuation N/M 17.4x Lower Multiple ABT
Revenue Growth (YoY) Growth N/A +14.5% Higher Growth ABT
Operating Margin (TTM) Profitability N/A 15.7% Higher Margin ABT
Net Profit Margin Profitability N/A 9.8% Higher Margin ABT
Return on Equity (ROE) Capital Efficiency N/A 9.1% Higher ROE ABT
52-Week Range Position Momentum 50% ($0โ€“$1) 42% ($82โ€“$131) Stronger Trend AXNX
Beta / 30D Volatility Risk Regime N/A 0.04ฮฒ ยท 32% Vol Lower Realized Risk ABT
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite AXNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AXNX vs ABT Buy Guide
AXNX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AXNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABT CONSOLIDATION
64d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live ABT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AXNX nor ABT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.